Argus
•
Apr 25, 2025
Bristol-Myers Squibb Company: HOLD as Legacy Portfolio declines drag on results
Summary
Bristol-Myers Squibb is a leading worldwide biopharmaceutical company. Its products focus on oncology, immunology, and cardiovascular conditions. The company completed its merger with Celgene
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
Upgrade
Related Reports
Analyst Report: AbbVie Inc.
The Argus Innovation Model Portfolio
Apr 25, 2025
•
TRGP, BLK, AAPL, JPM, ADI, AXON, URI, ADP, COST, V, WM, LLY, SPGI, CME, GE, PANW, NFLX, META, NVDA, CEG, SYK, BSX, ORCL, PWR, SCHW, RCL, ISRG, AJG, AMZN, CRM
Technical Assessment: Neutral in the Intermediate-Term
Apr 25, 2025
•
CRWD, GILD
Analyst Report: Gilead Sciences, Inc.
Analyst Report: Merck & Co., Inc.
View more related reports
Analyst Profile
Jasper Hellweg
Associate Analyst: Growth Pharmaceutical, Medical Technology & Financial Technology
At Argus Research, Jasper covers the Growth Pharmaceutical, Medical Technology, and Financial Technology companies. He received his undergraduate degree from Boston University, graduating cum laude with a Bachelor of Science degree in Business Administration with concentrations in Entrepreneurship and Marketing. Prior to joining Argus, Jasper worked in a variety of industries, ranging from investment tradeshow management to musical instrument manufacturing. He started his career at Argus in the Research department and has since widened his scope to also include becoming a regular contributor for the Market Movers and Market Digest publications, the Vickers Weekly Insider Report and Argus’ bespoke research on IPOs.
